Regeneron Tries To Put Focus On PD-1 Program, Not Sluggish Autoimmune Sales

Regeneron promised big things for PD-1 inhibitor cemiplimab during its first quarter earnings call, including studies to test its potential in lung cancer compared to Merck's Keytruda. It hopes to launch the antibody in a smaller indication later this year.